ScreenerHero

BLSM BlossomHill Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · bhtherapeutics.com
16.61USD-3.93%Mkt Cap: 527.95M $P/E: —

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clin…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap527.95M USD
Enterprise Value734.38M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-60.55M USD
Revenue/Share—
Last Price16.61 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees69
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.37
PEG—
EV/EBITDA-8.67
EV/Revenue—
P/S—
P/B-0.30
EPS (TTM)-4.70
EPS (Forward)-3.95
52W Range
15.2511% of range27.99
52W High27.99 USD
52W Low15.25 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE45.97%
ROA-37.16%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-46.92M USD
CapEx (TTM)1.07M USD
FCF Margin—
FCF Yield—
Net Debt-72.00M USD
Net Debt/EBITDA0.85
Balance Sheet
Debt/Equity-0.17
Current Ratio5.42
Quick Ratio5.12
Book Value/Sh-57.53 USD
Cash/Share3.00 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)35.40 USD
Upside (mean)+113.1%
Target Range30.00 USD – 40.00 USD
30.00+113.1% to mean40.00
# Analysts5
Ownership
Shares Out.31.78M
Float17.74M
Insiders12.71%
Institutions30.56%
Short Interest
Short Ratio0.8d
Short % Out.0.45%
Shares Short137.57K
Short (prev mo.)111.89K
Technical
SMA 5019.84 (-16.3%)
SMA 20019.84 (-16.3%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)213.18K
Avg Vol (10d)219.34K
Technical Indicators
RSI (14)37.8
MACD-0.5424
MACD Signal0.2913
MACD Hist.-0.8337
BB Upper27.82 USD
BB Middle21.66 USD
BB Lower15.50 USD
BB Width56.89%
ATR (14)1.986 USD
Vol Ratio (20d)1.01x